THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3)

C Edwards,F Blanco,J Crowley,C Hu,C Birbara,K Shah

doi:10.1136/annrheumdis-2015-eular.2889

THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3)

C Edwards, F Blanco + Show 4 more

https://doi.org/10.1136/annrheumdis-2015-eular.2889

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2015
Citations: 5

Affiliation: University Hospital Southampton NHS Foundation Trust, Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de A Coruña, Bakersfield College, Bristol-Myers Squibb (Switzerland), University of Massachusetts Chan Medical School

#Celgene Corporation #Prior Conventional Disease-modifying Antirheumatic Drugs + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundApremilast (APR), an oral phosphodiesterase 4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 3 compared the efficacy and safety of APR with placebo (PBO) in patients with...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.